Lanjia Lin

2.8k total citations · 1 hit paper
13 papers, 718 citations indexed

About

Lanjia Lin is a scholar working on Epidemiology, Hepatology and Oncology. According to data from OpenAlex, Lanjia Lin has authored 13 papers receiving a total of 718 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Epidemiology, 7 papers in Hepatology and 3 papers in Oncology. Recurrent topics in Lanjia Lin's work include Hepatitis B Virus Studies (8 papers), Hepatitis C virus research (7 papers) and Liver Disease Diagnosis and Treatment (5 papers). Lanjia Lin is often cited by papers focused on Hepatitis B Virus Studies (8 papers), Hepatitis C virus research (7 papers) and Liver Disease Diagnosis and Treatment (5 papers). Lanjia Lin collaborates with scholars based in United States, France and Spain. Lanjia Lin's co-authors include Anuj Gaggar, G. Mani Subramanian, John G. McHutchison, Edward Gane, Wendy Verret, Florence Dalenc, Sara M. Tolaney, Komal Jhaveri, Eva Ciruelos and Aditya Bardia and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Gastroenterology.

In The Last Decade

Lanjia Lin

12 papers receiving 707 citations

Hit Papers

Sacituzumab Govitecan in Hormone Receptor–Positive/Human ... 2022 2026 2023 2024 2022 50 100 150
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Sacituzumab Govitecan in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
    2022 176 citations Hope S. Rugo, Aditya Bardia et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lanjia Lin United States 9 409 354 225 137 78 13 718
Vincent Leroy France 17 545 1.3× 636 1.8× 112 0.5× 70 0.5× 35 0.4× 41 945
Ashley Stueck Canada 13 240 0.6× 466 1.3× 144 0.6× 78 0.6× 53 0.7× 39 763
Hirofumi Kamachi Japan 18 286 0.7× 623 1.8× 218 1.0× 142 1.0× 47 0.6× 51 932
Chen‐Chun Lin Taiwan 14 477 1.2× 921 2.6× 142 0.6× 139 1.0× 34 0.4× 36 1.1k
Wenge Xing China 14 193 0.5× 262 0.7× 127 0.6× 154 1.1× 15 0.2× 55 619
Miho Nakao Japan 8 729 1.8× 765 2.2× 308 1.4× 67 0.5× 77 1.0× 17 1.2k
Silvia Gaia Italy 17 740 1.8× 783 2.2× 122 0.5× 94 0.7× 20 0.3× 60 1.1k
Jean-Pierre Bronowicki France 13 520 1.3× 738 2.1× 89 0.4× 74 0.5× 31 0.4× 18 894
Xu Zhu China 18 144 0.4× 469 1.3× 246 1.1× 160 1.2× 99 1.3× 75 876

Countries citing papers authored by Lanjia Lin

Since Specialization
Citations

This map shows the geographic impact of Lanjia Lin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lanjia Lin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lanjia Lin more than expected).

Fields of papers citing papers by Lanjia Lin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lanjia Lin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lanjia Lin. The network helps show where Lanjia Lin may publish in the future.

Co-authorship network of co-authors of Lanjia Lin

This figure shows the co-authorship network connecting the top 25 collaborators of Lanjia Lin. A scholar is included among the top collaborators of Lanjia Lin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lanjia Lin. Lanjia Lin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
Colevas, A. Dimitrios, Venessa Chin, John Park, et al.. (2023). 675 Safety and tolerability of magrolimab combination therapy in patients with recurrent or metastatic head and neck squamous cell carcinoma (RM-HNSCC). SHILAP Revista de lepidopterología. A765–A766.
2.
Rugo, Hope S., Aditya Bardia, Frederik Marmé, et al.. (2022). Sacituzumab Govitecan in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer. Journal of Clinical Oncology. 40(29). 3365–3376. 176 indexed citations breakdown →
3.
4.
Subbiah, Vivek, Ulka N. Vaishampayan, Sonam Puri, et al.. (2022). A phase 2, multiarm study of anti-CD47 antibody, magrolimab, in combination with docetaxel in patients with locally advanced or metastatic solid tumors.. Journal of Clinical Oncology. 40(6_suppl). TPS584–TPS584. 2 indexed citations
5.
Cathcart, Andrea L., Henry Lik‐Yuen Chan, Neeru Bhardwaj, et al.. (2018). No Resistance to Tenofovir Alafenamide Detected through 96 Weeks of Treatment in Patients with Chronic Hepatitis B Infection. Antimicrobial Agents and Chemotherapy. 62(10). 39 indexed citations
6.
7.
Ricco, G., Marı́a Buti, Masao Omata, et al.. (2017). Comparative antiviral efficacy with higher ALT normalization of tenofovir alafenamide (TAF) versus tenofovir disoproxil fumarate (TDF) in HBeAg-negative, genotype D chronic hepatitis B. Digestive and Liver Disease. 49(1). e63–e63. 1 indexed citations
8.
Lok, Anna S., Calvin Q. Pan, Steven-Huy Han, et al.. (2016). Randomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis B. Journal of Hepatology. 65(3). 509–516. 141 indexed citations
9.
Kadayıfçı, Abdurrahman, George Papatheodoridis, MF Yuen, et al.. (2015). Characterization of HBsAg decline in the Tenofovir disoproxil fumarate (TDF) and peginterferon alfa 2A (PEG) combination study for chronic hepatitis B (CHB). Hepatology International. 1 indexed citations
10.
Chan, Henry Lik‐Yuen, Magdy Elkhashab, Huy N. Trinh, et al.. (2015). Association of baseline vitamin D levels with clinical parameters and treatment outcomes in chronic hepatitis B. Journal of Hepatology. 63(5). 1086–1092. 51 indexed citations
11.
Marcellin, Patrick, Marı́a Buti, Robert A. de Man, et al.. (2014). Kinetics of hepatitis B surface antigen loss in patients with HBeAg-positive chronic hepatitis B treated with tenofovir disoproxil fumarate. Journal of Hepatology. 61(6). 1228–1237. 80 indexed citations
12.
Chan, Henry Lik‐Yuen, C. K. Chan, Aric J. Hui, et al.. (2014). Effects of Tenofovir Disoproxil Fumarate in Hepatitis B e Antigen-Positive Patients With Normal Levels of Alanine Aminotransferase and High Levels of Hepatitis B Virus DNA. Gastroenterology. 146(5). 1240–1248. 115 indexed citations
13.
Lin, Lanjia, Dipankar Bandyopadhyay, Stuart R. Lipsitz, & Debajyoti Sinha. (2009). Association Models for Clustered Data with Binary and Continuous Responses. Biometrics. 66(1). 287–293. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Vincent Leroy Breakdown of academic impact, for papers by Ashley Stueck Breakdown of academic impact, for papers by Hirofumi Kamachi Breakdown of academic impact, for papers by Chen‐Chun Lin Breakdown of academic impact, for papers by Wenge Xing Breakdown of academic impact, for papers by Miho Nakao Breakdown of academic impact, for papers by Silvia Gaia Breakdown of academic impact, for papers by Jean-Pierre Bronowicki Breakdown of academic impact, for papers by Xu Zhu
Rankless by CCL
2026